
Brepocitinib tied to better dermatomyositis skin and itch
Shownotes
Editor's Pick: Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial (JAMA Dermatology, 2026)
Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic drug safety and the cardiometabolic interface, new targeted therapy data in inflammatory and neutrophilic skin disease, risk stratification in skin cancer, and a pair of papers that together make a strong case for looking below the neck in acne. Let's dive in.
This week's papers:
- Cardiometabolic Associations of Dermatological Treatments. Part I: Systemic Therapies.. Journal of the American Academy of Dermatology 2026
- Cardiometabolic Associations of Dermatological Treatments. Part II: Targeted and Biologic Therapies.. Journal of the American Academy of Dermatology 2026
- Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.. JAMA Dermatology 2026
- A Delphi Consensus on Tildrakizumab Dosing and Titration in Moderate-to-Severe Plaque Psoriasis.. Acta Dermato-Venereologica 2026
- Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma.. Journal of the American Academy of Dermatology 2026
- Comorbidity-Guided Management of Pyoderma Gangrenosum: A Clinical Guide to Emerging Therapeutic Targets.. Journal of the American Academy of Dermatology 2026
- Global Disparities in Access to Dermatological Care.. JAMA Dermatology 2026
- Laser and Energy-Based Device Use in Skin of Color: A Clinical Review of Safety, Efficacy, and Best Practices.. Journal of the American Academy of Dermatology 2026
- Truncal Acne Is Independently Associated with Stigmatization, Poorer Treatment Adherence and Greater Healthcare Utilization: A 20-country Survey.. Acta Dermato-Venereologica 2026
- Effectiveness, safety and tolerability of Ozenoxacin 2% lotion vs Clindamycin 1% lotion in mild to moderate truncal acne: An open label randomized controlled clinical trial.. Clinical and Experimental Dermatology 2026